KR20220161423A - 레지니페라톡신 투여에 의한 covid-19와 관련된 폐 염증성 질환의 치료 - Google Patents

레지니페라톡신 투여에 의한 covid-19와 관련된 폐 염증성 질환의 치료 Download PDF

Info

Publication number
KR20220161423A
KR20220161423A KR1020227037621A KR20227037621A KR20220161423A KR 20220161423 A KR20220161423 A KR 20220161423A KR 1020227037621 A KR1020227037621 A KR 1020227037621A KR 20227037621 A KR20227037621 A KR 20227037621A KR 20220161423 A KR20220161423 A KR 20220161423A
Authority
KR
South Korea
Prior art keywords
rtx
pulmonary
composition according
disease
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227037621A
Other languages
English (en)
Korean (ko)
Inventor
알렉시스 나하마
헨리 홍준 지
어빙 에이치. 주커
한준 왕
Original Assignee
소렌토 쎄라퓨틱스, 인코포레이티드
보드 오브 리젠츠 오브 디 유니버시티 오브 네브라스카
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 소렌토 쎄라퓨틱스, 인코포레이티드, 보드 오브 리젠츠 오브 디 유니버시티 오브 네브라스카 filed Critical 소렌토 쎄라퓨틱스, 인코포레이티드
Publication of KR20220161423A publication Critical patent/KR20220161423A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020227037621A 2020-03-30 2021-03-12 레지니페라톡신 투여에 의한 covid-19와 관련된 폐 염증성 질환의 치료 Ceased KR20220161423A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063002165P 2020-03-30 2020-03-30
US63/002,165 2020-03-30
US202063122858P 2020-12-08 2020-12-08
US63/122,858 2020-12-08
PCT/US2021/022089 WO2021202084A1 (en) 2020-03-30 2021-03-12 Treating pulmonary inflammatory disease associated with covid-19 by administering resiniferatoxin

Publications (1)

Publication Number Publication Date
KR20220161423A true KR20220161423A (ko) 2022-12-06

Family

ID=75340289

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227037621A Ceased KR20220161423A (ko) 2020-03-30 2021-03-12 레지니페라톡신 투여에 의한 covid-19와 관련된 폐 염증성 질환의 치료

Country Status (8)

Country Link
US (1) US20230143545A1 (https=)
EP (1) EP4125871A1 (https=)
JP (2) JP2023519853A (https=)
KR (1) KR20220161423A (https=)
CN (1) CN115666551A (https=)
AU (1) AU2021248861A1 (https=)
CA (1) CA3173611A1 (https=)
WO (1) WO2021202084A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300072A (en) * 2020-08-11 2023-03-01 Sorrento Therapeutics Inc Treatment of pneumonia by nerve ablation
WO2025153517A1 (en) 2024-01-15 2025-07-24 Grünenthal GmbH Treating knee joint pain by injecting resiniferatoxin at ultra low doses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2187193B (en) 1986-02-27 1989-11-08 Gerald Scott Controllably and swiftly degradable polymer compositions and films and other products made therefrom
US5021450A (en) 1989-05-30 1991-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
US5232684A (en) 1990-06-29 1993-08-03 The United States Of America As Represented By The Department Of Health And Human Services Labelled resiniferatoxin, compositions thereof, and methods for using the same
GB9826359D0 (en) * 1998-12-01 1999-01-27 Glaxo Group Ltd Novel receptors
CA2880855A1 (en) 2012-08-03 2014-02-06 Mestex Ag Resiniferatoxin solution
EP3131541A4 (en) * 2014-04-14 2018-02-14 Flex Pharma, Inc. Ion channel activators and methods of use
US20200129472A1 (en) * 2017-02-09 2020-04-30 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of peripheral artery disease
MX2020002692A (es) * 2017-09-11 2020-10-14 Sorrento Therapeutics Inc Formulacion de resiniferatoxina.

Also Published As

Publication number Publication date
EP4125871A1 (en) 2023-02-08
CN115666551A (zh) 2023-01-31
CA3173611A1 (en) 2021-10-07
JP2023519853A (ja) 2023-05-15
US20230143545A1 (en) 2023-05-11
AU2021248861A1 (en) 2022-10-13
WO2021202084A1 (en) 2021-10-07
JP2026042884A (ja) 2026-03-11

Similar Documents

Publication Publication Date Title
JP2026042884A (ja) レシニフェラトキシンを投与することによるｃｏｖｉｄ－１９と関連する肺炎症性疾患の処置
KR20080103108A (ko) 신경 장애 치료를 위한 ｌｈ 또는 ｈｃｇ 및 ｅｐｏ의 투여방법
Pulman et al. The erythropoietin-derived peptide ARA290 reverses mechanical allodynia in the neuritis model
US20230301700A1 (en) Treating Pulmonary Inflammatory Disease by Neural Ablation
US20250090637A1 (en) Methods of inhibiting cerebral inflammation
Yin et al. Peptide OM-LV20 exerts neuroprotective effects against cerebral ischemia/reperfusion injury in rats
Hooper et al. Nociceptive pulmonary‐cardiac reflexes are altered in the spontaneously hypertensive rat
Bubalo et al. Anaesthetic sparing effect of local anaesthesia of the ovarian pedicle during ovariohysterectomy in dogs
Keegan et al. Pulmonary edema after resection of a fourth ventricle tumor: possible evidence for a medulla-mediated mechanism
KR20100136494A (ko) 아포에쿼린 함유 조성물 및 이의 사용 방법
Cohen Blood-brain barrier to d-tubocurarine
Lujan et al. Targeted ablation of cardiac sympathetic neurons reduces the susceptibility to ischemia-induced sustained ventricular tachycardia in conscious rats
BR112012008821A2 (pt) uso de neuregulina para tratar lesões nervosas periféricas.
Yılmaz Anesthesia management for carotid endarterectomy
Sandkühler et al. Pentobarbital, in subanesthetic doses, depresses spinal transmission of nociceptive information but does not affect stimulation-produced descending inhibition in the cat
Kim et al. Effect of low dose ketamine to prevent remifentanil-induced cough: a randomized, double-blind, placebo controlled trial
Yalcin et al. The effect of centrally administered erythropoietin on cardiovascular and respiratory system of anaesthetized rats
Díaz-Casares et al. Role of the parabrachial complex in the cardiorespiratory response evoked from hypothalamic defense area stimulation in the anesthetized rat
US20240415859A1 (en) Use of isorhoifolin and derivative thereof in promoting nerve repair
KETAMINE Master of Veterinary Science
Swetha A Comparative Clinical Study of Intravenous Esmolol and Nitroglycerin for Attenuation of Hemodynamic Response to Laryngoscopy and Endotracheal Intubation in Patients Undergoing Elective Surgery
Kavya A Comparative Study Of Effect Of Rapid Crystalloid Preload And Intravenous Ephedrine In Management Of Hypotension Due To Subarachanoid Block In Elective Caesarean Section
BRANCH-X COMPARISON OF DEXMEDETOMIDINE WITH CLONIDINE AS AN ADJUVANT TO BUPIVACAINE IN SUPRACLAVICULAR BRACHIAL PLEXUS BLOCK
Kumar Comparative Study to Evaluate the Quality of Anaesthesia with Nitroglycerine and Magnesium Sulphate as Adjuvants to Lignocaine in Intravenous Regional Anaesthesia
TAMIL et al. A CLINICAL COMPARISON BETWEEN BUPIVACAINE (PLAIN) AND BUPIVACAINE-MIDAZOLAM IN BRACHIAL PLEXUS BLOCK VIA SUPRACLAVICULAR APPROACH

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601